Autonomic Technologies, through its Realeve brand, is pioneering innovative treatment systems aimed at addressing central nervous system (CNS) conditions. Central to their approach is the Pulsante™ micro-neurostimulator system, which is the first externally powered implantable micro-neuromodulation device. This technology has been successfully implanted in over 700 patients, demonstrating long-term effectiveness in treating cluster headaches. The Pulsante system utilizes a battery-free, wireless SPG (sphenopalatine ganglion) microstimulation implant that can be activated by a handheld device, allowing for minimally invasive treatment options. This system not only provides therapeutic benefits but also incorporates data collection capabilities for continuous monitoring of patient outcomes.

In addition to its application for cluster headaches, the Pulsante system shows promise in enhancing blood-brain barrier (BBB) permeability and improving outcomes for patients suffering from acute ischemic strokes. The proprietary technology includes a custom Application Specific Integrated Circuit (ASIC) that facilitates bidirectional communication, power management, and therapy delivery. The ability to control therapy through a wireless remote empowers patients, making the treatment process more user-friendly and effective. Overall, Realeve's commitment to advancing neuroscience through the Pulsante system reflects a significant step forward in the treatment of CNS disorders.

United States

Autonomic Technologies is a medical device company that focuses on the development and commercialization of innovative therapies for autonomic disorders, particularly severe headaches.

Autonomic Technologies

Company Details